Author

Jan Förster

German Cancer Research CenterORCID 0000-0002-1587-7732Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Annette PascheniD· 2 shared A. Hoewner· 1 shared Alexander R. SchrammiD· 1 shared Alexander RoeschiD· 1 shared Alpaslan TasdoganiD· 1 shared Barbara T. GrünwaldiD· 1 shared Batool Shannan· 1 shared Björn ScheffleriD· 1 shared

Activity by Year

2021-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Annette PaschenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Redirecting resistance evolution in BRAFV600 melanoma by inhibition of the peroxiredoxin-thioredoxin system

Stefanie Egetemaier, Heike Chauvistré, Renáta Váraljai, Yichao Hua, Smiths Lueong, Samira Makhzami, Nalini Srinivas, Jan Förster, Vivien Ullrich, Simone Stupia, Valéria Schroeder, Sarah Scharfenberg, A. Hoewner, Batool Shannan, Jens Thomas Siveke, , Alexander Roesch

This study identifies KDM5B's role in regulating the PRDX/TXN ROS detoxification system in melanoma DTPs, showing that PRDX inhibition increases ROS vulnerability and delays resistance to MAPK inhibition.

bioRxiv · Mar 10, 2025 · PreprintCancer Biology

Microphaser - a small-scale phasing approach for improved personalized neopeptidome creation

Jan Förster, David Laehnemann, Annette Paschen, Alexander R. Schramm, Martin Schüler, Johannes Köster

Microphaser improves haplotyping in cancer samples to create a more accurate neopeptidome for neoantigen prediction.

bioRxiv · Aug 11, 2021 · PreprintBioinformatics